Epigenetic Regulation and Tumor Suppressive Function of lncRNA EP300-AS1 in Nasopharyngeal Carcinoma Through Activation of TFAP2C Binding to CST6: Implications for Diagnosis, Prognosis, and Therapy

Authors

Chengliang Xing, The First Affiliated Hospital of Hianan Medical University
Shun Ding, The First Affiliated Hospital of Hianan Medical University
Tingting Duan, The First Affiliated Hospital of Hianan Medical University
Zhiqun Li, The First Affiliated Hospital of Hianan Medical University
Jinren Yan, The First Affiliated Hospital of Hinan Medical University
Yu Kuang, University of Nevada, Las VegasFollow
Qibing Liu, The First Affiliated Hospital of Hinan Medical University
Zhonglin Mu, The First Affiliated Hospital of Hinan Medical University

Document Type

Article

Publication Date

3-30-2025

Publication Title

American Journal of Cancer Research

Volume

15

Issue

3

First page number:

894

Last page number:

928

Abstract

The long non-coding RNA EP300-AS1 (lncRNA EP300-AS1), identified as a potential regulatory factor in various cancers, remains underexplored in nasopharyngeal carcinoma (NPC). This study investigated EP300-AS1’s regulatory mechanisms in NPC, particularly its interaction with transcription factor AP-2 Gamma (TFAP2C) and its effect on cystatin E/M (CST6) expression. Employing clinical samples and NPC cell lines, we conducted in vitro and in vivo xenograft experiments to assess the impacts of modulating EP300-AS1 expression. Techniques such as CCK8, migration, scratch, apoptosis assays, cell cycle analysis, immunoblotting, and fluorescence experiments elucidated EP300-AS1’s role in NPC. The interaction between EP300-AS1 and TFAP2C in regulating CST6 expression was verified using FISH, ChIP, RNA pull-down, and silver staining assays. Results indicated lower expression levels of EP300-AS1 and CST6 in NPC, with EP300-AS1 suppression inhibiting cell proliferation, migration, and invasion, while promoting apoptosis and maintaining the cell cycle in the G1 phase. EP300-AS1 also modulated epithelialmesenchymal transition (EMT) marker expression, suggesting a role in metastasis control. Conclusively, EP300-AS1 acts as a potential tumor suppressor in NPC by interacting with TFAP2C and targeting CST6, offering novel biomarkers and therapeutic targets through its influence on methylation and the tumor microenvironment.

Keywords

IncRNA EP300-AS1; CST6; nasopharyngeal carcinoma; prognosis

Disciplines

Oncology | Respiratory Tract Diseases

File Format

pdf

File Size

13400 KB

Language

English

Rights

IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Repository Citation

Xing, C., Ding, S., Duan, T., Li, Z., Yan, J., Kuang, Y., Liu, Q., Mu, Z. (2025). Epigenetic Regulation and Tumor Suppressive Function of lncRNA EP300-AS1 in Nasopharyngeal Carcinoma Through Activation of TFAP2C Binding to CST6: Implications for Diagnosis, Prognosis, and Therapy. American Journal of Cancer Research, 15(3), 894-928.
http://dx.doi.org/10.62347/MCYV5235